🟢 Health ETF (ARKG) is trading 3% up on September 14, 2026, as genomic-biotech names gain

ARKG is trading at $46.94 (+3.03%) as genomic-biotech names attract buying.

• ARKG is outperforming the broader market; the S&P 500 Health Care sector was previously modestly lower.
• Concentrated exposure to 10x Genomics, Twist Bioscience, Tempus AI, CRISPR Therapeutics, and Personalis can amplify sector-specific gains.
• Positive Akeso ivonescimab lung-cancer trial supports biotech sentiment, though Akeso is not identified as a dominant ARKG holding; higher Treasury yields and rate-hike expectations remain offsetting risks. The move appears genomic-biotech-driven, not macro-driven.